IMPACT OF PHARMACOGENOMICS ON PHARMACOKINETIC OF BETA BLOCKERS
| dc.contributor.author | Zolotaikina Marharyta | |
| dc.contributor.author | Fedorytenko Roman | |
| dc.contributor.author | Kurmanska Larysa | |
| dc.contributor.author | Kirkilevska Liudmila | |
| dc.date.accessioned | 2024-10-30T14:31:19Z | |
| dc.date.available | 2024-10-30T14:31:19Z | |
| dc.date.issued | 2024-07-29 | |
| dc.description.abstract | Beta adrenergic blockers (β‐blockers) antagonize beta-1, beta-2 adrenergic receptors, and have been widely used for cardiovascular therapy, as well as treatment of disorders such as anxiety, thyrotoxicosis and glaucoma. | |
| dc.identifier.citation | Zolotaikina , M., Fedorytenko , R., Kurmanska , L., & Kirkilevska , L. (2024). IMPACT OF PHARMACOGENOMICS ON PHARMACOKINETIC OF BETA BLOCKERS. Collection of Scientific Papers «ΛΌГOΣ», (July 19, 2024; Boston, USA), 275–276. https://doi.org/10.36074/logos-19.07.2024.054 | |
| dc.identifier.doi | 10.36074/logos-19.07.2024.054 | |
| dc.identifier.isbn | 978-617-8312-06-0 | |
| dc.identifier.uri | https://ir.kmu.edu.ua/handle/123456789/270 | |
| dc.language.iso | en | |
| dc.publisher | P.C. Publishing House», United Kingdom | |
| dc.subject | Beta adrenergic blockers | |
| dc.subject | cardiovascular therapy | |
| dc.subject | treatment | |
| dc.title | IMPACT OF PHARMACOGENOMICS ON PHARMACOKINETIC OF BETA BLOCKERS | |
| dc.type | Thesis |